ES2544640T3 - Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de diversas enfermedades autoinmunes - Google Patents

Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de diversas enfermedades autoinmunes

Info

Publication number
ES2544640T3
ES2544640T3 ES13002792.3T ES13002792T ES2544640T3 ES 2544640 T3 ES2544640 T3 ES 2544640T3 ES 13002792 T ES13002792 T ES 13002792T ES 2544640 T3 ES2544640 T3 ES 2544640T3
Authority
ES
Spain
Prior art keywords
cooh
eleven
tat
treatment
signal transduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13002792.3T
Other languages
English (en)
Inventor
Christophe Bonny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xigen Inflammation Ltd
Original Assignee
Xigen Inflammation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen Inflammation Ltd filed Critical Xigen Inflammation Ltd
Application granted granted Critical
Publication of ES2544640T3 publication Critical patent/ES2544640T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)

Abstract

Péptido inhibidor de JNK consistente en una secuencia de aminoácidos de acuerdo con la SEC ID NO: 2 o péptido quimérico consistente en un primer dominio y un segundo dominio unidos mediante un enlace covalente, comprendiendo el primer dominio una secuencia de tráfico y consistiendo el segundo dominio en una secuencia inhibidora de JNK de acuerdo con la SEC ID NO: 2, para su uso en un método de tratamiento de un trastorno autoinmune cardiovasculares seleccionadas de entre Lupus, Lupus eritematoso y síndrome de Sjögren.

Description

imagen1
imagen2
imagen3
imagen4
E13002792
04-08-2015
Tabla 1
NOMBRE PEPTIDO/ SEQ.
SEC ID NO AA SECUENCIA
L-IB1(s)
1 19 RPKRPTTLNLFPQVPRSQD (NH2-RPKRPTTLNLFPQVPRSQD-COOH)
D-IB1(s)
2 19 DQSRPVQPFLNLTTPRKPR (NH2-DQSRPVQPFLNLTTPRKPR-COOH)
L-IB(genérico)(s)
3 19 NH2-Xn b-Xn a-RPTTLXLXXXXXXXQD-Xn b-COOH
D-IB(genérico) (s)
4 19 NH2-Xn b-DQXXXXXXXLXLTTPR-Xn a-Xn b-COOH
L-TAT
5 10 GRKKRRQRRR (NH2-GRKKRRQRRR-COOH)
D-TAT
6 10 RRRQRRKKRG (NH2-RRRQRRKKRG-COOH)
L-genérico-TAT (s)
7 11 NH2-Xn b-RKKRRQRRR-Xn b-COOH
D-genérico-TAT (s)
8 11 NH2-Xn b-RRRQRRKKR-Xn b-COOH
L-TAT-IB1(s)
9 31 GRKKRRQRRRPPRPKRPTTLNLFPQVPRSQD (NH2-GRKKRRQRRRPPRPKRPTTLNLFPQVPRSQD-COOH)
L-TAT-IB (genérico) (s)
10 29 NH2-Xn b-RKKRRQRRR-Xn b-Xn a-RPLXLXXXXXXXQD-Xn b-COOH
D-TAT-IB1(s)
11 31 DQSRPVQPFLNLTTPRKPRPPRRRQRRKKRG (NH2-DQSRPVQPFLNLTTPRKPRPPRRRQRRKKRG-COOH)
D-TAT-IB (genérico) (s)
12 29 NH2-Xn b-DQXXXXXXXLXLTTPR-Xn a-Xn b-RRRQRRKKR-Xn b-COOH
IB1-largo
13 29 PGTGCGDTYRPKRPTTLNLFPQVPRSQDT (NH2-PGTGCGDTYRPKRPTTLNLFPQVPRSQDT -COOH)
IB2-largo
14 27 IPSPSVEEPHKHRPTTLRLTTLGAQDS (NH2-IPSPSVEEPHKHRPTTLRLTTLGAQDS -COOH)
c-Jun
15 29 GAYGYSNPKILKQSMTLNLADPVGNLKPH (NH2-GAYGYSNPKILKQSMTLNLADPVGNLKPH -COOH)
ATF2
16 29 TNEDHLAVHKHKHEMTLKFGPARNDSVIV (NH2-TNEDHLAVHKHKHEMTLKFGPARNDSVIV -COOH)
L-IB1
17 23 DTYRPKRPTTLNLFPQVPRSQDT (NH2-DTYRPKRPTTLNLFPQVPRSQDT -COOH)
D-IB1
18 23 TDQSRPVQPFLNLTTPRKPRYTD (NH2-TDQSRPVQPFLNLTTPRKPRYTD -COOH)
L-IB (genérico)
19 19 XRPTTLXLXXXXXXXQDS/TX (NH2-XRPTTLXLXXXXXXXQDS/TX -COOH)
D-IB (genérico)
20 19 XS/TDQXXXXXXXLXLTTPRX (NH2-XS/TDQXXXXXXXLXLTTPRX -COOH)
L-genérico-TAT
21 17 XXXXRKKRRQRRRXXXX (NH2-XXXXRKKRRQRRRXXXX -COOH)
D-genérico-TAT
22 17 XXXXRRRQRRKKRXXXX (NH2-XXXXRRRQRRKKRXXXX -COOH)
L-TAT-IB1
23 35 GRKKRRQRRRPPDTYRPKRPTTLNLFPQVPRSQDT (NH2-GRKKRRQRRRPPDTYRPKRPTTLNLFPQVPRSQDT -COOH)
L-TAT-IB (genérico)
24 42 XXXXXXRKKRRQRRRXXXXXXXXRPTTLXLXXXXXXXQDS/TX (NH2-XXXXXXXRKKRRQRRRXXXXXXXXRPTTLXLXXXXXXXQDS/TX -COOH)
D-TAT-IB1
25 35 TDQSRPVQPFLNLTTPRKPRYTDPPRRRQRRKKRG (NH2-TDQSRPVQPFLNLTTPRKPRYTDPPRRRQRRKKRG -COOH)
D-TAT-IB (genérico)
26 42 XT/SDQXXXXXXXLXLTTPRXXXXXXXXRRRQRRKKRXXXXXXX(NH2-XT/SDQXXXXXXXLXLTTPRXXXXXXXXRRRQRRKKRXXXXXXX -COOH)
L-TAT-IB1(s1)
27 30 RKKRRQRRRPPRPKRPTTLNLFPQVPRSQD (NH2-RKKRRQRRRPPRPKRPTTLNLFPQVPRSQD-COOH)
L-TAT-IB1(s2)
28 30 GRKKRRQRRRXn cRPKRPTTLNLFPQVPRSQD (NH2-GRKKRRQRRRXn cRPKRPTTLNLFPQVPRSQD-COOH)
L-TAT-IB1(s3)
29 29 RKKRRQRRRXn cRPKRPTTLNLFPQVPRSQD (NH2-RKKRRQRRRXn cRPKRPTTLNLFPQVPRSQD-COOH)
D-TAT-IB1(s1)
30 30 DQSRPVQPFLNLTTPRKPRPPRRRQRRKKR (NH2-DQSRPVQPFLNLTTPRKPRPPRRRQRRKKR-COOH)
D-TAT-IB1(s2)
31 30 DQSRPVQPFLNLTTPRKPRXn cRRRQRRKKRG (NH2-DQSRPVQPFLNLTTPRKPRXn cRRRQRRKKRG-COOH)
D-TAT-IB1(s3)
32 29 DQSRPVQPFLNLTTPRKPRXn cRRRQRRKKR (NH2-DQSRPVQPFLNLTTPRKPRXn cRRRQRRKKR-COOH)
L-IB1(s1)
33 13 TLNLFPQVPRSQD(NH2-TLNLFPQVPRSQD-COOH)
E13002792
04-08-2015
L-IB1(s2)
34 13 TTLNLFPQVPRSQ(NH2-TTLNLFPQVPRSQ-COOH)
L-IB1(s3)
35 13 PTTLNLFPQVPRS(NH2-PTTLNLFPQVPRS-COOH)
L-IB1(s4)
36 13 RPTTLNLFPQVPR(NH2-RPTTLNLFPQVPR-COOH)
L-IB1(s5)
37 13 KRPTTLNLFPQVP(NH2-KRPTTLNLFPQVP-COOH)
L-IB1(s6)
38 13 PKRPTTLNLFPQV(NH2-PKRPTTLNLFPQV-COOH)
L-IB1(s7)
39 13 RPKRPTTLNLFPQ(NH2-RPKRPTTLNLFPQ-COOH)
L-IB1(s8)
40 12 LNLFPQVPRSQD(NH2-LNLFPQVPRSQD-COOH)
L-IB1(s9)
41 12 TLNLFPQVPRSQ(NH2-TLNLFPQVPRSQ-COOH)
L-IB1(s10)
42 12 TTLNLFPQVPRS(NH2-TTLNLFPQVPRS-COOH)
L-IB1(s11)
43 12 PTTLNLFPQVPR(NH2-PTTLNLFPQVPR-COOH)
L-IB1(s12)
44 12 RPTTLNLFPQVP(NH2-RPTTLNLFPQVP-COOH)
L-IB1(s13)
45 12 KRPTTLNLFPQV(NH2-KRPTTLNLFPQV-COOH)
L-IB1(s14)
46 12 PKRPTTLNLFPQ(NH2-PKRPTTLNLFPQ-COOH)
L-IB1(s15)
47 12 RPKRPTTLNLFP(NH2-RPKRPTTLNLFP-COOH)
L-IB1(s16)
48 11 NLFPQVPRSQD(NH2-NLFPQVPRSQD-COOH)
L-IB1(s17)
49 11 LNLFPQVPRSQ(NH2-LNLFPQVPRSQ-COOH)
L-IB1(s18)
50 11 TLNLFPQVPRS(NH2-TLNLFPQVPRS-COOH)
L-IB1(s19)
51 11 TTLNLFPQVPR(NH2-TTLNLFPQVPR-COOH)
L-IB1(s20)
52 11 PTTLNLFPQVP(NH2-PTTLNLFPQVP-COOH)
L-IB1(s21)
53 11 RPTTLNLFPQV(NH2-RPTTLNLFPQV-COOH)
L-IB1(s22)
54 11 KRPTTLNLFPQ(NH2-KRPTTLNLFPQ-COOH)
L-IB1(s23)
55 11 PKRPTTLNLFP(NH2-PKRPTTLNLFP-COOH)
L-IB1(s24)
56 11 RPKRPTTLNLF(NH2-RPKRPTTLNLF-COOH)
L-IB1(s25)
57 10 LFPQVPRSQD(NH2-LFPQVPRSQD-COOH)
L-IB1(s26)
58 10 NLFPQVPRSQ(NH2-NLFPQVPRSQ-COOH)
L-IB1(s27)
59 10 LNLFPQVPRS(NH2-LNLFPQVPRS-COOH)
L-IB1(s28)
60 10 TLNLFPQVPR(NH2-TLNLFPQVPR-COOH)
L-IB1(s29)
61 10 TTLNLFPQVP(NH2-TTLNLFPQVP-COOH)
L-IB1(s30)
62 10 PTTLNLFPQV(NH2-PTTLNLFPQV-COOH)
L-IB1(s31)
63 10 RPTTLNLFPQ(NH2-RPTTLNLFPQ-COOH)
L-IB1(s32)
64 10 KRPTTLNLFP(NH2-KRPTTLNLFP-COOH)
L-IB1(s33)
65 10 PKRPTTLNLF(NH2-PKRPTTLNLF-COOH)
L-IB1(s34)
66 10 RPKRPTTLNL(NH2-RPKRPTTLNL-COOH)
D-IB1(s1)
67 13 QPFLNLTTPRKPR(NH2-QPFLNLTTPRKPR-COOH)
D-IB1(s2)
68 13 VQPFLNLTTPRKP(NH2-VQPFLNLTTPRKP-COOH)
D-IB1(s3)
69 13 PVQPFLNLTTPRK(NH2-PVQPFLNLTTPRK-COOH)
D-IB1(s4)
70 13 RPVQPFLNLTTPR(NH2-RPVQPFLNLTTPR-COOH)
D-IB1(s5)
71 13 SRPVQPFLNLTTP(NH2-SRPVQPFLNLTTP-COOH)
D-IB1(s6)
72 13 QSRPVQPFLNLTT(NH2-QSRPVQPFLNLTT-COOH)
D-IB1(s7)
73 13 DQSRPVQPFLNLT(NH2-DQSRPVQPFLNLT-COOH)
D-IB1(s8)
74 12 PFLNLTTPRKPR(NH2-PFLNLTTPRKPR-COOH)
D-IB1(s9)
75 12 QPFLNLTTPRKP(NH2-QPFLNLTTPRKP-COOH)
D-IB1(s10)
76 12 VQPFLNLTTPRK(NH2-VQPFLNLTTPRK-COOH)
D-IB1(s11)
77 12 PVQPFLNLTTPR(NH2-PVQPFLNLTTPR-COOH)
D-IB1(s12)
78 12 RPVQPFLNLTTP(NH2-RPVQPFLNLTTP-COOH)
D-IB1(s13)
79 12 SRPVQPFLNLTT(NH2-SRPVQPFLNLTT-COOH)
D-IB1(s14)
80 12 QSRPVQPFLNLT(NH2-QSRPVQPFLNLT-COOH)
D-IB1(s15)
81 12 DQSRPVQPFLNL(NH2-DQSRPVQPFLNL-COOH)
D-IB1(s16)
82 11 FLNLTTPRKPR(NH2-FLNLTTPRKPR-COOH)
D-IB1(s17)
83 11 PFLNLTTPRKP(NH2-PFLNLTTPRKP-COOH)
D-IB1(s18)
84 11 QPFLNLTTPRK(NH2-QPFLNLTTPRK-COOH)
D-IB1(s19)
85 11 VQPFLNLTTPR(NH2-VQPFLNLTTPR-COOH)
D-IB1(s20)
86 11 PVQPFLNLTTP(NH2-PVQPFLNLTTP-COOH)
D-IB1(s21)
87 11 RPVQPFLNLTT(NH2-RPVQPFLNLTT-COOH)
D-IB1(s22)
88 11 SRPVQPFLNLT(NH2-SRPVQPFLNLT-COOH)
D-IB1(s23)
89 11 QSRPVQPFLNL(NH2-QSRPVQPFLNL-COOH)
D-IB1(s24)
90 11 DQSRPVQPFLN(NH2-DQSRPVQPFLN-COOH)
D-IB1(s25)
91 10 DQSRPVQPFL(NH2-DQSRPVQPFL-COOH)
D-IB1(s26)
92 10 QSRPVQPFLN(NH2-QSRPVQPFLN-COOH)
D-IB1(s27)
93 10 SRPVQPFLNL(NH2-SRPVQPFLNL-COOH)
D-IB1(s28)
94 10 RPVQPFLNLT(NH2-RPVQPFLNLT-COOH)
D-IB1(s29)
95 10 PVQPFLNLTT(NH2-PVQPFLNLTT-COOH)
D-IB1(s30)
96 10 VQPFLNLTTP(NH2-VQPFLNLTTP-COOH)
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34

Claims (1)

  1. imagen1
ES13002792.3T 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de diversas enfermedades autoinmunes Active ES2544640T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/EP2008/004341 2008-05-30
PCT/EP2008/004341 WO2009143865A1 (en) 2008-05-30 2008-05-30 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases

Publications (1)

Publication Number Publication Date
ES2544640T3 true ES2544640T3 (es) 2015-09-02

Family

ID=40347935

Family Applications (5)

Application Number Title Priority Date Filing Date
ES13002792.3T Active ES2544640T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de diversas enfermedades autoinmunes
ES09753692T Active ES2400988T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de diversas enfermedades
ES13002793.1T Active ES2531963T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de enfermedades cancerosas
ES12000663.0T Active ES2481915T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales jnk para el tratamiento de diversas enfermedades
ES12000665T Active ES2443347T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de enfermedades cardiovasculares

Family Applications After (4)

Application Number Title Priority Date Filing Date
ES09753692T Active ES2400988T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de diversas enfermedades
ES13002793.1T Active ES2531963T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de enfermedades cancerosas
ES12000663.0T Active ES2481915T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales jnk para el tratamiento de diversas enfermedades
ES12000665T Active ES2443347T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de enfermedades cardiovasculares

Country Status (17)

Country Link
US (2) US9006185B2 (es)
EP (6) EP2650007B1 (es)
JP (3) JP5485265B2 (es)
CN (2) CN104147591B (es)
AR (1) AR070864A1 (es)
AU (1) AU2009253346B2 (es)
CA (1) CA2725545A1 (es)
CY (4) CY1114725T1 (es)
DK (5) DK2650007T3 (es)
ES (5) ES2544640T3 (es)
HK (1) HK1221413A1 (es)
HR (1) HRP20150116T1 (es)
HU (1) HUE026798T2 (es)
PL (5) PL2296684T3 (es)
PT (4) PT2650007E (es)
SI (1) SI2650008T1 (es)
WO (2) WO2009143865A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010048446A2 (en) 2008-10-22 2010-04-29 Genentech, Inc. Modulation of axon degeneration
US20100183633A1 (en) * 2008-12-04 2010-07-22 University Of Massachusetts Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
AU2010362444B2 (en) * 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
EP2627346B1 (en) * 2010-10-14 2016-03-23 Xigen Inflammation Ltd. Cell-permeable peptide inhibitors of the jnk signal transduction pathway for use in the treatment of uveitis
CN101974083A (zh) * 2010-10-20 2011-02-16 中国医学科学院医学生物学研究所 抗hsv1病毒感染的人源hirrp蛋白分子
WO2013091670A1 (en) * 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
ES2870085T3 (es) * 2013-06-26 2021-10-26 Xigen Inflammation Ltd Inhibidores peptídicos permeables a células de la ruta de transducción de señales de JNK para el tratamiento de la cistitis
WO2015197097A1 (en) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2015197194A2 (en) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2016055160A2 (en) * 2014-10-08 2016-04-14 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206426A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2015197098A1 (en) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CN103911462B (zh) * 2014-04-03 2015-06-10 河北国际旅行卫生保健中心 黄热、乙型脑炎、基孔肯雅、西尼罗的鉴别检测方法及引物和探针
JP2017516493A (ja) * 2014-04-04 2017-06-22 フェリジオーニ、マルコ グルタメート興奮毒性により起こる疾患を治療するための細胞透過性ペプチド系
EP3160989A2 (en) * 2014-06-26 2017-05-03 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CN104250640A (zh) * 2014-08-22 2014-12-31 普莱柯生物工程股份有限公司 猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用
US20180170983A1 (en) * 2015-06-26 2018-06-21 Xigen Inflammation Ltd. New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment
EP3464312A4 (en) * 2016-06-02 2019-11-27 Celgene Corporation ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS
US12486318B2 (en) 2016-06-15 2025-12-02 Yale University Anti-guanosine antibody as a molecular delivery vehicle
WO2019152808A1 (en) * 2018-02-01 2019-08-08 Yale University Compositions and methods for inhibition of nuclear-penetrating antibodies
CA3112549A1 (en) * 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
CN116003530B (zh) * 2022-12-27 2023-12-15 西湖大学 一种针对白细胞介素-6的d-蛋白抑制剂及其应用
CN121142059B (zh) * 2025-11-17 2026-02-17 吉林农业大学 一种基于dia质谱技术评估微塑料神经毒性的方法及系统

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195304B (it) 1981-12-22 1988-10-12 Anic Spa Metodo per la preparazione di gem-diammino derivati n-monoacilati
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
IT1190389B (it) 1985-09-19 1988-02-16 Eniricerche Spa Esapeptidi ad attivita' ipotensiva
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IT1227907B (it) 1988-12-23 1991-05-14 Eniricerche S P A Milano Sclav Procedimento per la sintesi di peptidi retro-inversi e nuovi intermediin tale procedimento
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5840313A (en) 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
WO1992018138A1 (en) 1991-04-10 1992-10-29 The General Hospital Corporation Mammalian gap-43 compositions and methods of use
US5994108A (en) 1991-11-05 1999-11-30 Board Of Regents, The University Of Texas System Mutant TAR virus and transdominant tat mutants as pharmacological agents
US5350835A (en) 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
CA2131620A1 (en) 1992-03-20 1993-09-30 Louis C. Smith A dna transporter system and method of use
DK0636028T3 (da) 1992-04-03 2004-07-12 Univ California Selvorganiserende polynucleotidleveringssystem omfattende et amfipatisk kationisk peptid
EP0673385A4 (en) 1992-08-13 1995-11-29 Gen Hospital Corp COMPOSITIONS CONCERNING GAP-43 MAMMALS AND METHODS OF USE.
CA2135642C (en) 1992-08-21 1999-12-14 James G. Barsoum Tat-derived transport polypeptides
CN1091138A (zh) 1992-08-27 1994-08-24 迪金研究有限公司 疫苗
US5545551A (en) 1992-08-28 1996-08-13 Mt. Sinai School Of Medicine Of The City University Of New York Cloning and expression of pur protein
KR950703640A (ko) 1992-10-09 1995-09-20 가일 케이,나우톤. 간 보존 세포(liver reserve cells)
EP0693939A1 (de) 1993-04-14 1996-01-31 Roche Diagnostics GmbH Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen
WO1995014772A1 (en) 1993-11-12 1995-06-01 Kenichi Matsubara Gene signature
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
WO1996034093A1 (en) 1995-04-25 1996-10-31 Baxter International Inc. Composition containing collagenase and chymopapain for isolating hepatocytes and pancreatic islet cells
BR9610058A (pt) 1995-07-28 1999-07-27 Marie Curie Cancer Care Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células
CA2232750A1 (en) 1995-09-21 1997-03-27 Innapharma, Inc. Peptides and peptidomimetics inhibiting the oncogenic action of p21 ras
IE80466B1 (en) 1995-11-10 1998-07-29 Elan Corp Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US5877282A (en) 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
US6187817B1 (en) 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
WO1998023781A1 (en) 1996-11-26 1998-06-04 Johns Hopkins University Ligand detection system and methods of use thereof
US5989814A (en) 1997-04-01 1999-11-23 Reagents Of The University Of California Screening methods in eucaryotic cells
US5880261A (en) 1997-04-03 1999-03-09 Waeber; Gerard Transcription factor Islet-Brain 1 (IB1)
AU6972798A (en) 1997-04-18 1998-11-13 University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
WO1998051325A2 (en) 1997-05-15 1998-11-19 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods
US20040152084A1 (en) 2003-01-31 2004-08-05 Slattum Paul M. Compounds and processes for single-pot attachment of a label to nucleic acid
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
FR2767323B1 (fr) 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
EP0897002A3 (en) 1997-08-14 2001-10-04 Smithkline Beecham Plc U62317, a protein having a JNK-binding domain
AU9402898A (en) 1997-09-26 1999-04-23 Washington University Cell death agonists
US6420031B1 (en) 1997-11-03 2002-07-16 The Trustees Of Princeton University Highly transparent non-metallic cathodes
ES2221213T3 (es) 1997-10-20 2004-12-16 F. Hoffmann-La Roche Ag Inhibidores de kinasa biciclicos.
US6270956B1 (en) 1997-12-11 2001-08-07 The Salk Institute For Biological Studies Transcriptional coactivator that interacts with Tat protein and regulates its binding to TAR RNA, methods for modulating Tat transactivation, and uses therefor
EP0947524A1 (en) 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
EP1082310A4 (en) 1998-04-29 2001-09-12 Univ Georgetown Methods of identifying and using hla binding compounds as hla-agonists and antagonists
WO1999058692A2 (en) 1998-05-13 1999-11-18 Incyte Pharmaceuticals, Inc. Human apoptosis associated proteins
WO1999058561A1 (fr) 1998-05-14 1999-11-18 Pasteur Merieux Serums & Vaccins Mimotopes du virus de l'hepatite c
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6740524B1 (en) 1998-06-18 2004-05-25 Dnavec Research, Inc. Nucleic acid transfer phage
CA2328457A1 (en) 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6552167B1 (en) 1998-08-28 2003-04-22 Gryphon Therapeutics, Inc. Polyamide chains of precise length
WO2000018407A1 (en) 1998-09-25 2000-04-06 Cephalon, Inc. Methods for preventing/treating damage to sensory hair cells and cochlear neurons
US6656474B1 (en) 1999-01-15 2003-12-02 Regeneron Pharmaceuticals, Inc. Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
JP2003506071A (ja) 1999-05-28 2003-02-18 アポプトシス テクノロジー，アイエヌシー． アポトーシスを制御する化合物および方法ならびにアポトーシスを制御する化合物を製造およびスクリーニングする方法
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
WO2000075118A1 (en) * 1999-06-03 2000-12-14 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)
WO2000075164A1 (en) 1999-06-07 2000-12-14 Mirus Corporation COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
CA2381425A1 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6881825B1 (en) 1999-09-01 2005-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues
US20030104622A1 (en) 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6610820B1 (en) 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20010046489A1 (en) 1999-12-06 2001-11-29 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US6586403B1 (en) 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
US6960648B2 (en) 2000-10-13 2005-11-01 Universite De Lausanne Intracellular delivery of biological effectors
US20040014212A1 (en) 2000-10-17 2004-01-22 Elliott Robert Bartlett Preparation and xenotransplantation or porcine islets
US20030077826A1 (en) 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
CA2437248A1 (en) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
WO2002062396A2 (en) 2001-02-08 2002-08-15 University Of Medicine And Dentistry Of New Jersey Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
MXPA03007358A (es) 2001-02-16 2004-12-13 Cellgate Inc Transportadores que contienen porciones de arginina separadas.
JP4234999B2 (ja) 2001-04-06 2009-03-04 トマス ジェファソン ユニバーシティ 治療標的としてのｈｉｖ−１ｖｉｆタンパク質の多量体形成
DE10117281A1 (de) 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
US20060216706A1 (en) 2001-07-17 2006-09-28 Tang Y T Proteins associated with cell growth, differentiation, and death
WO2004045535A2 (en) 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
IL160915A0 (en) * 2001-09-19 2004-08-31 Aventis Pharma Sa Indolizines inhibiting kinase proteins
US7803749B2 (en) 2002-01-09 2010-09-28 Xigen Sa Peptide inhibitors of MKK7 kinase binding to insulin binding proteins
AU2003217961B2 (en) * 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2004022580A2 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
CA2497977A1 (en) 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
DK1408114T3 (da) 2002-10-11 2007-05-07 Imvision Gmbh Modulære antigen-transporter molekyler (MAT-molekyler) til modulation af immunreaktioner, tilhörende konstrukter, fremgangsmåder og anvendelser
US20040186052A1 (en) 2002-10-24 2004-09-23 Suhasini Iyer Cytomodulating peptides and methods for treating neurological disorders
WO2004054501A2 (en) 2002-11-18 2004-07-01 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US20050019366A1 (en) 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
JP4787150B2 (ja) * 2003-03-06 2011-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｊｎｋ阻害剤
US20080090770A1 (en) 2003-04-11 2008-04-17 Belmares Michael P Modulation of Muc1 Mediated Signal Transduction
CA2523672C (en) 2003-04-29 2012-07-17 Avi Biopharma, Inc. Compositions for enhancing transport of molecules into cells
CA2529752A1 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
KR100685345B1 (ko) 2004-03-27 2007-02-22 학교법인조선대학교 세포사 유도 펩타이드
JP5080241B2 (ja) * 2004-04-08 2012-11-21 メルク セローノ ソシエテ アノニム Ｊｎｋ阻害剤およびスクロスポリンを含んでなる組成物
JP2008510766A (ja) 2004-08-27 2008-04-10 ゲーペーツェー ビオテック アーゲー ピリミジン誘導体
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
EP1656951A1 (en) 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
ZA200709240B (en) * 2005-04-29 2009-06-24 Celgene Corp Solid forms of 1-(5-(IH-1,2,4-triazol-5-yl)(IH-indazol-3-yl)-3-(2-piperidylethoxy)benzene
US20070015779A1 (en) 2005-04-29 2007-01-18 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US20070003531A1 (en) * 2005-06-30 2007-01-04 University Of Connecticut Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) * 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
JP2009514876A (ja) * 2005-11-03 2009-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼのための化合物および組成物
US8066998B2 (en) 2006-06-30 2011-11-29 Kim Laboratories, Inc. Antibodies for norovirus
US10045953B2 (en) 2006-07-06 2018-08-14 Case Western Reserve University Ceramide composition and method of use
WO2008094208A2 (en) 2006-08-02 2008-08-07 Northwestern University Protein kinase targeted therapeutics
EP2066319B1 (en) * 2006-09-08 2012-02-01 F. Hoffmann-La Roche AG Benzotriazole kinase modulators
GB0702259D0 (en) 2007-02-06 2007-03-14 Eisai London Res Lab Ltd 7-azaindole derivatives
HUE024146T2 (en) 2008-05-07 2016-02-29 Univ California Medical filling and enrichment of eye surface lubrication
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US20100183633A1 (en) 2008-12-04 2010-07-22 University Of Massachusetts Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
MX2011008276A (es) 2009-02-06 2011-12-14 Elan Pharm Inc Inhibidores de quinasa jun n-terminal.
CN102365093A (zh) 2009-03-30 2012-02-29 参天制药株式会社 用于视网膜疾病的预防剂或治疗剂和使用JNK(c-Jun氨基末端激酶)抑制肽预防或治疗视网膜疾病的方法以及所述肽的用途
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
EP2627346B1 (en) 2010-10-14 2016-03-23 Xigen Inflammation Ltd. Cell-permeable peptide inhibitors of the jnk signal transduction pathway for use in the treatment of uveitis
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US8471027B2 (en) 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206426A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases

Also Published As

Publication number Publication date
PL2650008T3 (pl) 2015-05-29
EP2650008B1 (en) 2014-12-17
EP2296684B1 (en) 2012-12-05
SI2650008T1 (sl) 2015-03-31
US9006185B2 (en) 2015-04-14
PL2650007T3 (pl) 2015-12-31
CY1115357T1 (el) 2017-01-04
PL2489361T3 (pl) 2014-08-29
EP2650008A1 (en) 2013-10-16
DK2489361T3 (da) 2014-06-30
CA2725545A1 (en) 2009-12-03
ES2531963T3 (es) 2015-03-23
JP2015232008A (ja) 2015-12-24
JP5824085B2 (ja) 2015-11-25
HK1175102A1 (en) 2013-06-28
AU2009253346A1 (en) 2009-12-03
WO2009144037A1 (en) 2009-12-03
CN104147591B (zh) 2017-04-12
CN102112149A (zh) 2011-06-29
JP5485265B2 (ja) 2014-05-07
HK1150305A1 (en) 2011-11-25
ES2400988T3 (es) 2013-04-16
HUE026798T2 (en) 2016-07-28
CY1116175T1 (el) 2017-02-08
AR070864A1 (es) 2010-05-12
CN104147591A (zh) 2014-11-19
EP2650007B1 (en) 2015-05-20
HK1186988A1 (en) 2014-03-28
ES2481915T3 (es) 2014-07-31
US9610330B2 (en) 2017-04-04
DK2296684T3 (da) 2013-03-25
CY1116633T1 (el) 2017-03-15
EP2296684A1 (en) 2011-03-23
PT2491942E (pt) 2013-12-23
PL2491942T3 (pl) 2014-03-31
EP2491942B1 (en) 2013-10-23
JP2011524861A (ja) 2011-09-08
PT2650007E (pt) 2015-08-04
PL2296684T3 (pl) 2013-05-31
JP2014111646A (ja) 2014-06-19
EP2985031B1 (en) 2017-04-12
HK1186989A1 (en) 2014-03-28
HK1174839A1 (en) 2013-06-21
WO2009143865A1 (en) 2009-12-03
PT2489361E (pt) 2014-05-29
DK2650008T3 (en) 2015-02-09
PT2650008E (pt) 2015-03-02
US20110183888A1 (en) 2011-07-28
EP2489361B1 (en) 2014-04-16
DK2650007T3 (en) 2015-07-06
AU2009253346B2 (en) 2014-07-10
DK2491942T3 (da) 2014-01-13
US20150246099A1 (en) 2015-09-03
EP2985031A1 (en) 2016-02-17
EP2650007A1 (en) 2013-10-16
CY1114725T1 (el) 2016-10-05
ES2443347T3 (es) 2014-02-19
HK1221413A1 (en) 2017-06-02
EP2489361A1 (en) 2012-08-22
EP2491942A1 (en) 2012-08-29
HRP20150116T1 (en) 2015-03-27

Similar Documents

Publication Publication Date Title
ES2544640T3 (es) Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de diversas enfermedades autoinmunes
DE602005019465D1 (de) Bi- und trizyklische substituierte phenyl-methanone als inhibitoren von glycin-i (glyt-1)-transportern zur behandlung der alzheimer-krankheit
EA201070422A1 (ru) Производные оксадиазола
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
AR112816A2 (es) Compuestos que inhiben el enlace de la proteína smac al inhibidor de proteínas de apoptosis (iap)
ECSP10010303A (es) (dihidro)pirrolo[2,1-a]isoquinolinas
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
TW200738742A (en) Antiviral compounds
CR9591A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
PE20170898A1 (es) Inhibidor de cinasa aurora a
GB2433936A (en) Therapeutic peptides comprising sequences derived from CDR2 or CDR3 of trem-1 and uses thereof to inhibit sepsis
MX2009011276A (es) Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad.
ATE543795T1 (de) Kondensierte bicyclische carbonsäureamidderivate zur verwendung als cxcr2-inhibitoren bei der behandlung von entzündungen
CL2009000619A1 (es) Compuestos derivados de carbazol, inhibidores de la proteina hsp90; procedimiento para preparar los compuestos; compuestos intermediarios, composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en el tratamiento del cancer.
ATE417832T1 (de) Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes
DK1727551T3 (da) Farmaceutisk sammensætning omfattende et benzodiazepinderivat og en inhibitor af RSV-fusionsproteinet
ECSP055783A (es) Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevención de diabetes
PE20180412A1 (es) Compuestos inhibidores de la senalizacion de la via de notch
EA201070423A1 (ru) Диарильные соединения оксадиазолов
MY155400A (en) Anti cxcr4 antibodies for the treatment of hiv
DK1727550T3 (da) Farmaceutisk sammensætning omfattende et benzodiazepin-derivat og en inhibitor for RVS-fusions-proteinet
EA200800157A1 (ru) Антагонисты npy, способ их получения и применение
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
CL2008001321A1 (es) Compuestos derivados de (cromanil o tiocromanil o naftalenil)-1,3-dihidroimidazol-2-tiona, inhibodores de dopamina betahidroxilasa; procedimiento de preparacion de enantiomeros (r) y (s) separados o en mezcla; composicion farmaceutica; y su uso en el tratamiento de ansiedad, jaqueca, trastornos cardiovasculares, entre otros.